Preventing immunotherapy-related diarrhea in advanced cancer
Treatments studied
Part of Digestive system clinical trials.
This study tests whether vedolizumab, a drug that reduces gut inflammation, can prevent diarrhea caused by immunotherapy (a type of cancer treatment). It is for adults with advanced melanoma, lung, or kidney cancer who have a stool marker of inflammation early in treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with advanced (stage III or IV) melanoma, lung, or kidney cancer that cannot be removed with surgery.
- You are scheduled to start immunotherapy (a type of cancer treatment) and have had a stool test within 4 weeks of your first dose showing elevated calprotectin (a marker of inflammation).
- You do not have conditions like Crohn's disease, ulcerative colitis, or have had an ileostomy, colostomy, or short bowel syndrome.
- You do not have active infections, untreated tuberculosis, or untreated hepatitis B.
- You are not pregnant or breastfeeding, and if you can become pregnant, you agree to use effective birth control during the study and for 6 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational oral medication (SER-155) for people whose diarrhea is caused by immunotherapy. It aims to calm the gut and reduce symptoms without needing stronger drugs.
This study tests whether taking mesalamine can prevent colitis (bowel inflammation) in people with advanced melanoma who are treated with ipilimumab plus nivolumab. It may help reduce dangerous stomach or bowel side effects from this cancer treatment.
This trial studies whether infliximab can treat stomach inflammation in the colon (colitis) or frequent diarrhea caused by immune checkpoint cancer drugs. It aims to improve symptoms safely for adults with certain solid cancers.
This trial tests a new treatment, KAN-004, for people with diarrhea or colon inflammation caused by cancer immunotherapy. It aims to help manage these side effects.
This early-phase study tests whether changing your gut bacteria with a fecal transplant can improve diarrhea or colitis caused by cancer immunotherapy. It may help people whose symptoms have not fully settled with standard treatments like steroids and other immune-blocking medicines.
This trial tests whether a treatment called fecal microbiota transplant (FMT) — transferring healthy gut bacteria — can help relieve diarrhea and colitis caused by immunotherapy drugs. If you have melanoma or kidney cancer and are experiencing diarrhea after immunotherapy, this study may offer a new option.
Hear when a new IrAE trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.